Genentech/Biogen Idec Submit Rituxan sBLA For Rheumatoid Arthritis

Filing is second in two weeks for the biologic, following recent sBLA submission for front-line non-Hodgkin's lymphoma treatment.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet